我国发布第四批鼓励仿制药品目录

Core Viewpoint - The fourth batch of encouraged generic drug catalog includes 21 varieties and 47 specifications, focusing on patient treatment needs and addressing weak R&D areas in domestic companies [1] Group 1: Drug Categories - The catalog includes drugs for oncology, nervous system, assisted reproduction, and radioactive diagnosis [1] - New target and mechanism products are prioritized, such as a drug for alleviating moderate to severe itching in chronic kidney disease patients undergoing dialysis [1] Group 2: Drug Effectiveness and Recommendations - Products already recommended in first-line guidelines abroad are prioritized, like Suvorexant for treating insomnia, which addresses difficulties in falling asleep and reduces daytime drowsiness and fatigue [1] - The catalog also emphasizes low adverse reaction iterative products, such as progesterone vaginal sustained-release gel and suppositories for assisted reproduction, which mitigate injection-related side effects [1] Group 3: Accessibility and Clinical Practice - The selection process considers drug accessibility and prioritizes products with existing clinical practices in China, such as Deflazacort for treating Duchenne muscular dystrophy [1]